Women worry hormonal contraception will make them gain weight. Actually, the evidence on combined oral contraceptives (COCs) and weight gain is largely reassuring, regardless of what weight you begin at. A Cochrane meta-analysis of 49 trials found that the four trials with a placebo or no-method control group showed no evidence that COCs cause weight gain, and no substantial weight differences were found across 52 different comparisons of COC formulations. The Endocrine Society Clinical Practice Guideline similarly concluded that current data are insufficient to establish an effect of combination hormonal contraception on weight, this organization recommends women who have a BMI of over 30 or a BMI of over 27 with co-morbidities to barrier or IUD methods, thus recommend considering the potential impact of contraceptive choice on weight.
However, progestin-only methods differ in their weight profiles some studies in younger women show Depot medroxyprogesterone acetate (DMPA) is the contraceptive most consistently associated with weight gain — 0.63–8.04 kg after 1 year, with continued gain with ongoing use. What is important is to keep getting monitored. Women who gain >5% within 6 months of DMPA initiation are at high risk for continued gain. As with other discussions on weight management, it’s not just your body weight, but your body composition that may be at risk and one trial showed Desogestrel-only OC (75 μg) in perimenopausal women showed no significant change in total weight or BMI versus controls at 12 months, but did show a significant increase in fat mass percentage (+3.3%) with a corresponding decrease in fat-free mass. Though most studies show very little weight gain of those who are normal weight, most hormone contraception trials excluded obese women.
ACOG, family medicine/family planning organizations, and The Menopause Society counsel patients with obesity (BMI ≥30) or overweight with obesity-related comorbidities (BMI ≥27) regarding contraception with slightly different recommendations, but, there is broad agreement on several key points.
Obesity alone is not a contraindication to most contraceptive methods. Highly effective, long-acting reversible contraception (LARC) methods such as the levonorgestrel IUD, copper IUD, and etonogestrel implant are generally preferred because they are extremely effective and are not negatively affected by body weight. [societyfp.org], [societyfp.org]
ACOG position
ACOG follows the CDC U.S. Medical Eligibility Criteria (US MEC) framework.
Key points:
- Women with obesity should have access to the full range of contraceptive options. [guidelinecentral.com], [societyfp.org]
- IUDs and implants are considered appropriate and highly effective regardless of BMI. [societyfp.org], [societyfp.org]
- Combined hormonal contraceptives (CHCs) containing estrogen (pill, patch, ring) are generally acceptable in obesity alone (US MEC Category 2, meaning advantages generally outweigh risks), but clinicians should assess additional cardiovascular and thromboembolic risk factors. [ctcsrh.org], [societyfp.org]
- If obesity is accompanied by comorbidities such as:
- uncontrolled hypertension,
- prior VTE,
- thrombophilia,
- significant vascular disease,
- migraine with aura, then estrogen-containing methods may become relatively or absolutely contraindicated. [guidelinecentral.com], [societyfp.org]
Family medicine / Family Planning guidance
The American Academy of Family Physicians (AAFP) and Society of Family Planning similarly note:
- Hormonal contraceptives remain effective in women with overweight and obesity. [aafp.org], [stacks.cdc.gov]
- There is no consistent evidence that obesity substantially reduces efficacy of most hormonal methods. [aafp.org], [stacks.cdc.gov]
- The Society of Family Planning specifically recommends:
- offering the full range of contraceptive methods regardless of body weight;
- using person-centered counseling;
- discussing any potential weight-related risks and benefits;
- considering interactions with bariatric surgery or GLP-1 medications when relevant. [societyfp.org], [societyfp.org]
The Menopause Society (formerly NAMS)
For perimenopausal women with obesity:
- Contraception is still needed until menopause is confirmed because fertility persists despite declining ovarian function. [reproducti…access.org], [ajmc.com]
- The Menopause Society generally aligns with CDC and ACOG recommendations regarding contraceptive eligibility. [ajmc.com], [reproducti…access.org]
- In women with obesity and age-related cardiovascular risk factors, clinicians should carefully evaluate whether estrogen-containing contraceptives remain appropriate and may favor:
- LNG-IUD,
- copper IUD,
- implant,
- progestin-only pill, depending on comorbidities and symptom-management goals. [ajmc.com], [reproducti…access.org]
Practical recommendations for a patient with BMI ≥30 or BMI ≥27 + comorbidities
Generally considered excellent choices:
- Levonorgestrel IUD (Mirena, Liletta, etc.)
- Copper IUD
- Etonogestrel implant (Nexplanon)
These avoid estrogen-related VTE concerns and maintain excellent efficacy across BMI categories. [societyfp.org], [societyfp.org]
Use more caution with:
- Combined oral contraceptives
- Contraceptive patch
- Vaginal ring
especially if obesity coexists with hypertension, smoking, migraine with aura, diabetes with vascular disease, prior VTE, or multiple cardiovascular risk factors. [guidelinecentral.com], [societyfp.org]
One important distinction
The BMI ≥30 or BMI ≥27 with comorbidities threshold is primarily the obesity-treatment threshold used for anti-obesity medications, not a specific contraception threshold. Contraceptive eligibility is based more on the presence of obesity and the associated cardiovascular/VTE risk factors than on the BMI 27-versus-30 cutoff itself. [aafp.org], [societyfp.org]
